AbbVie (ABBV) has signed an agreement with the Trump administration, securing a tariff exemption

AbbVie's agreement with the Trump administration for a tariff exemption may bolster its competitive position in the biotechnology sector while mitigating potential cost impacts from tariffs.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Japanese Current Account (Nov) 3.674tln vs Exp. 3.594tln (Prev. 2.834tln, Rev. 2.834tln)

US President Trump posts "I never want Americans to pay higher Electricity bills because of Data Centers", says Microsoft (MSFT) will make a major change this week to make sure Americans do not "pick up the tab" for their power consumption

AbbVie (ABBV) has signed an agreement with the Trump administration, securing a tariff exemption

Australian Westpac Consumer Confidence Index (Jan) 92.9 vs. Exp. 97 (Prev. 94.5)

Japanese Finance Minister Katayama says there were some detailed proposals on rare earth supply chains during the meeting with the US

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could set a positive tone for investor sentiment towards AbbVie and similar firms, especially in the context of U.S. market dynamics. Watch for potential ripple effects on equity valuations, particularly within the pharmaceuticals and biotech space.

Related headlines

The whole workspace, free to try.

Try it free